Atherosclerosis and Lipoproteins |
Presented in part at the Scientific Conference on Hormonal, Metabolic, and Cellular Influences on Cardiovascular Disease in Women of the American Heart Association, San Diego, Calif, October 1921, 1995, and the 66th Congress of the European Atherosclerosis Society, Florence, Italy, July 1317, 1996.
From the Departments of Internal Medicine and Endocrinology, Laboratory of Lipid Metabolism, University Medical Center Utrecht, the Netherlands. Dr de Bruin is now at the Department of Medicine and Endocrinology, Maastricht University Medical School, Maastricht, Netherlands.
Correspondence to André P. van Beek, MD, PhD, Departments of Internal Medicine and Endocrinology, F02.124, PO Box 85.500, 3508 GA Utrecht, Netherlands. E-mail vanbeek.hopian{at}gironet.nl
| Abstract |
|---|
|
|
|---|
Key Words: chylomicrons estrogens coronary heart disease risk factors lipids
| Introduction |
|---|
|
|
|---|
We investigated whether the presence of natural menopause is associated with reduced protection from postprandial lipemia in normolipidemic women matched for age and body mass index.
| Methods |
|---|
|
|
|---|
20 IU/L).
All healthy women, ranging in age from 47 to 52 years, were eligible
for screening when they had a uterus and 2 ovaries in situ, used no
medication currently or in the preceding year, and did not smoke.
During a screening visit, the participants medical history was taken
with special attention to the menstrual cycle, and a physical
examination was performed. At this visit, plasma
cholesterol, TG, FSH, and estradiol levels were also
determined. All postmenopausal and premenopausal women who were
normolipidemic at screening (cholesterol <6.5 mmol/L
and TG <2.0 mmol/L, representing the 75th percentile
for Dutch women in this age group) and had body mass indices between 19
and 30 kg/m2 were enrolled in the study. All
participants gave their written informed consent before the study. The
study was approved by the ethical committee of the Academic
Hospital Utrecht.
Oral Fat-Tolerance Test
Cream consisting of 40% fat (wt/vol) with a ratio of
polyunsaturated to saturated fatty acid of 0.06, 0.001%
cholesterol (wt/vol), and 2.8% carbohydrates (wt/vol) was
given as a single fat source in a dose of 50 g
fat/m2 body surface area. Vitamin A was added to
the cream in a dose of 60 000 IU aqueous retinyl palmitate (RP)/50 g
fat (125 mL cream). Vitamin A, a lipid-soluble vitamin, is incorporated
in chylomicrons as RP and is a marker for these intestinal
lipoproteins. After an overnight fast of 12 hours, participants were
admitted to the clinical research center at 8 AM. Blood
samples were obtained before the test meal and hourly thereafter up to
12 hours in tubes containing EDTA. To prevent breakdown of RP, all
blood samples were protected from light. Water and decaffeinated coffee
or tea, but no food, were allowed during the test. None of the subjects
had diarrhea or other symptoms of malabsorption. The average cream fat
load was 88±7 g in postmenopausal and 88±6 g in premenopausal
women.
Laboratory Assays and Measurements
A rapid single-spin ultracentrifugation
method was used at hourly intervals to separate lipoproteins into a
fraction with a Svedberg flotation unit >1000 (Sf>1000) that contains
chylomicrons, large chylomicron remnants, and large hepatic
lipoproteins and a remaining infranatant fraction (Sf<1000) containing
small chylomicron remnants and all other
lipoproteins.14 15 Whole plasma and lipoprotein fractions
were assayed for cholesterol and TGs with commercial
enzymatic reagents. The concentration of RP was measured by
high-performance liquid chromatography. HDLs
were prepared by the heparin-MnCl2dextran
sulfate precipitation method. LDLs were prepared by density gradient
ultracentrifugation. Measurements of hormones were
performed in baseline blood samples. FSH and luteinizing hormone were
determined by ELISAs, estrone, and estradiol by competitive
radioimmunoassays.16 ApoE genotypes and
postheparin lipolytic enzyme activities were measured as
described.16
Statistical Analysis
Data are given as mean±SD. Postprandial responses are expressed
as TG or RP area under the time curve (AUC) or under the incremental
time curve (
AUC, ie, the increment after subtraction of
baseline concentrations) from baseline to 8 hours postprandially. The
unpaired t test was used to detect the significance of mean
differences. To correct for the potentially confounding effect of
baseline TGs, 13 postmenopausal women were matched to 19 premenopausal
women with 1 single criterion: a difference in plasma TG <0.05
mmol/L. If >1 premenopausal woman met the matching criterion, all case
subjects were selected and averaged out, resulting in a 1:1 matching.
To determine the significance of mean differences in this subgroup
analysis, a paired t test was used. Statistical
calculations were performed with SPSS 6.1 for Windows.
| Results |
|---|
|
|
|---|
|
Daily energy and fat intakes were not different for the 2 groups (data not shown). ApoE genotypes for the 2 groups were highly comparable: E2/E3 (postmenopausal, 0; premenopausal, 3), E2/E4 (2, 0), E3/E3 (15, 14), E3/E4 (5, 3) and E4/E4 (1, 1). Hepatic lipase activity was higher in postmenopausal women (409±53 versus 336±71 mU/mL; P<0.001). LPL activities were not different between the 2 groups (199±57 and 176±58 mU/mL for postmenopausal and premenopausal women, respectively).
Postprandial Responses
After an oral fat-tolerance test, time curves in postmenopausal
women for TGs (Figure
, panel A) and RP
(Figure
, panel B) were higher than in premenopausal women. The
mean (incremental) postprandial TG response (TG AUC and TG
AUC) and
chylomicron response (RP AUC) were significantly larger in
postmenopausal women (Table 2
). The
statistically significant differences clearly appeared in Sf>1000
lipoprotein fractions with both TGs and RP (ie, chylomicrons, large
chylomicron remnants, and large hepatic TG-rich lipoproteins) but were
also measured in Sf<1000 lipoproteins with RP (ie, mainly small
chylomicron remnants). All women in both groups had returned to fasting
plasma TG concentrations after 8 hours after ingestion of the test
meal, and TG levels continued to drop in the next 4 hours. This
decrease was more exaggerated in postmenopausal women. The mean
difference in plasma TGs between postmenopausal and premenopausal women
at baseline and at 8, 10, and 12 hours after the fat load was 30%,
15%, 7%, and 4%, respectively. To correct for the possible
confounding effects of fasting TGs, postmenopausal and premenopausal
women were precisely matched for baseline TGs (Table 3
). All matched pairs had fasting TG
levels <1.2 mmol/L, and differences in fasting TG in matched
pairs were not exceeding 0.05 mmol/L. Time curves for TGs and RP
(figure
, panels C and D, respectively) showed again that
postmenopausal women had higher postprandial lipemia than premenopausal
women. Despite identical fasting TGs, the mean (and incremental) plasma
TG responses (TG AUC and TG
AUC) were significantly higher in
postmenopausal women. The chylomicron response (RP AUC) was also higher
after the menopause. This difference was caused by the Sf>1000
lipoprotein fraction, which contained mainly the chylomicrons and large
chylomicron remnants.
|
|
|
| Discussion |
|---|
|
|
|---|
We studied nonsmoking women of similar age and body mass index, because smoking, obesity, and age influence both lipid metabolism and the occurrence of menopause.17 In theory, the selection of age-matched groups might be a problem, because the fact that menopause was reached at a different chronological age could be an indication of underlying differences between the groups that also relate to lipid metabolism.18 We believe that this is not the case, because no data exist in the literature to support such an idea. We studied 2 groups of healthy women within a narrow age limit who were at the lower and higher ends of the normal distribution for age at menopause. It is unlikely that underlying differences, rather than menopause per se, have blurred the study results. Age at menopause is determined primarily by the number of ovarian follicles.19
Menopausal changes in fasting plasma lipids in our study were highly comparable to those found by others in longitudinal5 20 or cross-sectional4 21 studies, with the exception of TGs. We found that fasting TGs were 30% higher in postmenopausal women. Other studies found no significant increase5 or higher levels after the menopause, with values ranging from 12%4 to 18%.21 This variability in findings can be explained in 2 ways. First, different definitions of menopausal status were used in the literature, and therefore, variable groups, with conceivably varying differences in plasma lipids, were identified. It is likely that changes in lipids are not instantaneous but rather gradual, expressing ongoing decline of ovarian function.20 Second, the distinct possibility should be recognized that regulation of plasma TGs in premenopausal women is different from that in postmenopausal women. Ninety percent of the premenopausal women had plasma TG levels <1.5 mmol/L at baseline, in contrast to only 75% of the postmenopausal women, whereas very low fasting TG concentrations (<0.5 mmol/L) were observed in both groups. Thus, after the menopause, there is a larger population-based variation in fasting TGs. This was also observed after an oral fat load, showing higher postchallenge peak TG levels and lower compensatory trough levels. Thus, concomitant with the loss of endogenous estrogens, the tight regulation of plasma TGs is lost.
The postprandial differences in TG and vitamin A in the Sf>1000 fractions suggest a difference in the metabolism of chylomicrons and large chylomicron remnants, because fat intake and postheparin lipoprotein lipase activity were similar. This can be explained in several ways. First, higher concentrations of hepatic TG-rich lipoproteins may have resulted in enhanced competition at the level of the common lipolytic pathway.22 However, after correction for endogenous TGs in the fasting state, these differences persisted. Second, there may have been a different composition of chylomicrons, eg, reduced size or different apoprotein composition. Furthermore, the deficiency of endogenous estrogens may lead to a decreased chylomicron clearance capacity. This is supported by a report on the effects of estrogen replacement on chylomicron metabolism in postmenopausal women.16
In conclusion, substantial and significant differences in postprandial lipid metabolism were found in women who differed only in their menopausal status and therefore in their endogenous estrogen production. The loss of protection from postprandial lipemia associated with the postmenopausal state potentially explains the lipid contribution to the increased risk of coronary artery disease and has the potential to be therapeutically corrected by nutritional or pharmaceutical interventions.
| Acknowledgments |
|---|
Received December 8, 1998; accepted March 24, 1999.
| References |
|---|
|
|
|---|
2. van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996;347:714718.[Medline] [Order article via Infotrieve]
3. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:11051110.[Abstract]
4. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis. 1993;98:8390.[Medline] [Order article via Infotrieve]
5. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med. 1989;321:641646.[Abstract]
6.
Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma
lipoprotein levels as predictors of cardiovascular
death in women. Arch Intern Med. 1993;153:22092216.
7. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham study. Am Heart J. 1987;114:413419.[Medline] [Order article via Infotrieve]
8.
Austin MA. Plasma triglyceride and
coronary heart disease. Arterioscler Thromb. 1991;11:214.
9.
Groot PHE, Van Stiphout WAHJ, Krauss XH, Jansen H, van
Tol A, Van Ramshorst E, Chin-On S, Hofman A, Creswell SR, Havekes L.
Postprandial lipoprotein metabolism in normolipidimic men
with and without coronary artery disease. Arterioscler
Thromb. 1991;11:653662.
10.
Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V,
Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of
triglyceride metabolism and coronary
artery disease: studies in the postprandial state. Arterioscler
Thromb.. 1992;12:13361345.
11. Weintraub MS, Grosskopf I, Rassin T, Miller H, Charach G, Rotmensch HH, Liron M, Rubinstein A, Laina A. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ. 1996;312:936939.
12. Meyer E, Westerveld HE, De Ruijter-Heijstek FC, Van Greevenbroek MMJ, Rienks R, Van Rijn HJM, Erkelens DW, De Bruin TWA. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study. Atherosclerosis. 1996;124:221235.[Medline] [Order article via Infotrieve]
13. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary sclerosis. Atherosclerosis. 1994;106:8397.[Medline] [Order article via Infotrieve]
14. Grundy SM, Mok HY. Chylomicron clearance in normal and hyperlipidemic man. Metabolism. 1976;25:12251239.[Medline] [Order article via Infotrieve]
15. Weintraub MS, Eisenberg S, Breslow JL. Different patterns of postprandial lipoprotein metabolism in normal and type IIa, type III and type IV hyperlipoproteinemics: effects of treatment with cholestyramine and gemfibrozil. J Clin Invest. 1987;79:11101119.
16. Westerveld HT, Kock LA, van Rijn HJ, Erkelens DW, De Bruin TWA. 17ß-Estradiol improves postprandial lipid metabolism in postmenopausal women. J Clin Endocrinol Metab. 1995;80:249253.[Abstract]
17.
Willett W, Stampfer MJ, Bain C, Lipnick R, Speizer FE,
Rosner B, Cramer D, Hennekens CH. Cigarette smoking, relative weight,
and menopause. Am J Epidemiol. 1983;117:651658.
18. Crook D, Seed M. Endocrine control of plasma lipoprotein metabolism: effects of gonadal steroids. Baillieres Clin Endocrinol Metab. 1990;4:851875.[Medline] [Order article via Infotrieve]
19. Ginsberg J. What determines the age at the menopause? BMJ. 1991;302:12881289.
20. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas. 1990;12:321331.[Medline] [Order article via Infotrieve]
21. Lindquist O, Bengtsson C. Serum lipids, arterial blood pressure and body weight in relation to the menopause: results from a population study of women in Goteborg, Sweden. Scand J Clin Lab Invest. 1980;40:629636.[Medline] [Order article via Infotrieve]
22. Brunzell JD, Hazzard WR, Porte D Jr, Bierman EL. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest. 1973;52:15781585.
This article has been cited by other articles:
![]() |
B. Fagerberg, H. Schuster, G. S. Birketvedt, S. Tonstad, K. P. Ohman, and I. Gause-Nilsson Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPAR{alpha}/{gamma} agonist, tesaglitazar Diabetes and Vascular Disease Research, September 1, 2007; 4(3): 174 - 180. [Abstract] [PDF] |
||||
![]() |
G. D. Kolovou, K. K. Anagnostopoulou, D. S. Damaskos, C. Mihas, S. Mavrogeni, G. Hatzigeorgiou, T. Theodoridis, D. P. Mikhailidis, and D. V. Cokkinos Gender Influence on Postprandial Lipemia in Heterozygotes for Familial Hypercholesterolemia Ann. Clin. Lab. Sci., January 1, 2007; 37(4): 335 - 342. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Christian, P. Y. Liu, S. Harrington, M. Ruan, V. M. Miller, and L. A. Fitzpatrick Intimal Estrogen Receptor (ER){beta}, But Not ER{alpha} Expression, Is Correlated with Coronary Calcification and Atherosclerosis in Pre- and Postmenopausal Women J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2713 - 2720. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Bittner Perspectives on Dyslipidemia and Coronary Heart Disease in Women J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1628 - 1635. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.B. Twickler, G.M. Dallinga-Thie, J.S. Cohn, and M.J. Chapman Elevated Remnant-Like Particle Cholesterol Concentration: A Characteristic Feature of the Atherogenic Lipoprotein Phenotype Circulation, April 27, 2004; 109(16): 1918 - 1925. [Full Text] [PDF] |
||||
![]() |
N. Mohanlal and R. R. Holman A Standardized Triglyceride and Carbohydrate Challenge: The oral triglyceride tolerance test Diabetes Care, January 1, 2004; 27(1): 89 - 94. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Fitzpatrick Hormones and the Heart: Controversies and Conundrums J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5609 - 5610. [Full Text] [PDF] |
||||
![]() |
M. G. Masding, A. J. Stears, G. C. Burdge, S. A. Wootton, and D. D. Sandeman Premenopausal Advantages in Postprandial Lipid Metabolism Are Lost in Women With Type 2 Diabetes Diabetes Care, December 1, 2003; 26(12): 3243 - 3249. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Horton, S. R. Commerford, M. J. Pagliassotti, and D. H. Bessesen Postprandial leg uptake of triglyceride is greater in women than in men Am J Physiol Endocrinol Metab, December 1, 2002; 283(6): E1192 - E1202. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E Roeters van Lennep, H.T. Westerveld, D.W. Erkelens, and E. E van der Wall Risk factors for coronary heart disease: implications of gender Cardiovasc Res, February 15, 2002; 53(3): 538 - 549. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Vega-Lopez, R. L. Vidal-Quintanar, and M. L. Fernandez Sex and hormonal status influence plasma lipid responses to psyllium Am. J. Clinical Nutrition, October 1, 2001; 74(4): 435 - 441. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Bravo, A. Cantafora, M. Avella, and K. M. Botham Metabolism of Chylomicron Cholesterol Is Delayed by Estrogen. An In Vivo Study in the Rat Experimental Biology and Medicine, February 1, 2001; 226(2): 112 - 118. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |